within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP58_DaclatasvirAsunaprevirAndBeclabuvir;

model DaclatasvirAsunaprevirAndBeclabuvir
  extends Pharmacolibrary.Drugs.ATC.J.J05AP58;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AP58</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>The fixed-dose combination of daclatasvir, asunaprevir and beclabuvir is an oral antiviral medication that was developed for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daclatasvir is an NS5A inhibitor, asunaprevir is an NS3 protease inhibitor, and beclabuvir is an NS5B polymerase inhibitor. The combination was developed for interferon-free treatment of HCV but has not received FDA approval and its global development was discontinued.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on healthy adult volunteers after administration of the fixed-dose combination tablet under fasting conditions.</p><h4>References</h4><ol><li><p>Eley, T, et al., &amp; Bertz, RJ (2015). Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. <i>Clinical pharmacokinetics</i> 54(12) 1205–1222. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0299-6&quot;>10.1007/s40262-015-0299-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26177803/&quot;>https://pubmed.ncbi.nlm.nih.gov/26177803</a></p></li><li><p>Osawa, M, et al., &amp; Garimella, T (2019). Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. <i>Clinical pharmacology in drug development</i> 8(6) 802–817. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.649&quot;>10.1002/cpdd.649</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30629858/&quot;>https://pubmed.ncbi.nlm.nih.gov/30629858</a></p></li><li><p>Esposito, I, et al., &amp; Trinks, J (2018). Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(6) 649–657. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1483336&quot;>10.1080/17425255.2018.1483336</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29855221/&quot;>https://pubmed.ncbi.nlm.nih.gov/29855221</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DaclatasvirAsunaprevirAndBeclabuvir;
